Entero Healthcare sees strong growth, expanding into MedTech

Entero Healthcare Solutions Limited reported significant growth for the quarter and half year ended September 30, 2025. Q2 FY26 revenue increased by 21% year-on-year to INR 1,570.9 crore, with gross profit rising 32% to INR 160.8 crore. EBITDA saw a substantial 46% increase to INR 62.1 crore, and profit after tax (PAT) grew by 41% to INR 36.6 crore. Gross margin improved by 84 basis points year-on-year to 10.2%, and EBITDA margin expanded by 69 basis points to 4.0%.

The company is on track to achieve INR 1,000 crore revenue from acquisitions, with INR 215 crore closed in H1 FY26 and an additional INR 330 crore closed in October 2026. MedTech acquisitions are a key focus, representing 61% of the acquisition mix, aligning with the company's strategy to expand into higher-margin segments. Return on Capital Employed (RoCE) improved to 13.8% in Q2 FY26 from 11.0% in Q2 FY25, and Net Working Capital (NWC) days improved to 63 days from 69 days.

Entero Healthcare is actively consolidating the fragmented Indian healthcare products distribution market, targeting a rise in market share for large/national distributors to 20-30% by FY28. The company’s pan-India presence now covers 490 districts, with 113 warehouses, serving over 85,300 retailers and 2,800 hospitals.